The company was honored with the Ingredient of the Year award in the Microbiome Modulation and the Beauty from Within category.
Gastroenterology, Oncology
The findings of a recent study highlight the importance of considering age-related immune changes and gut microbiota composition for developing personalized immunotherapy approaches.
Gastroenterology, Oncology
A recent study demonstrated causation between microbial DCA metabolism and anti-tumor CD8+ T cell response in colorectal cancer.
Industry
Bi104 is a microbiome-modifying biologic designed to diversify and modulate the gut microflora and metabolite profile.
Industry
AB-Biotics recently appointed to the IPA board of directors. What opportunities and future developments? We discussed this with Miquel Bonachera.
Cardiology
The findings of a recent study shed light on how the microbiota impacts cholesterol levels. They may also inform microbial-based interventions against high cholesterol.
Join SynBalance at Vitafoods Europe 2024, held at Palexpo, Switzerland from May 14th to May 16th.
Oncology
The findings of a recent study suggest that L. johnsonii or its metabolite IPA could be used as a microbial-based approach to improve a person’s response to immunotherapy.
Scientific research, No category
The intersection of gaming and science has birthed an innovative approach to scientific research and public engagement.
Industry
This unprecedented partnership signifies a concerted effort to address pressing microbiome-related challenges and advance health equity worldwide.